Faraday Future Announces FF Top Will Dismiss Lawsuit Against Co. And Board Of Directors; Co. Also Announces $100M In Committed Funding
Comprehensive Governance Resolution with FF Top
Faraday Future and its largest shareholder have reached an agreement regarding their governance dispute
FF Top will dismiss its lawsuit against the company and its
Amended 13D Filing Shows FF Top And FF Global Agreed To Cause All Actions In Court Of Chancery In Delaware To Be Dismissed Without Prejudice
Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.
Item 6 of the Schedule 13D is hereby supplemented as follows:
“On September 23, 2022, FF Global and FF
Moonlake Immunotherapeutics To Initiate Global Phase 2 Study Of The Nanobody Sonelokimab In Patients With Active Psoriatic Arthritis
MoonLake announces FDA clearance for Phase 2 clinical study of the Nanobody® sonelokimab in active psoriatic arthritis
Expected to enroll approximately 200 patients to assess the efficacy and safety of sonelokimab
Arcutis Announces Topline Results From ARRECTOR Pivotal Phase 3 Trial Of Roflumilast Foam 0.3% In Scalp And Body Psoriasis; Study Met Both Co-Primary Endpoints And All Secondary Endpoints
Study met both co-primary endpoints and all secondary endpoints
At week eight, 67.3% of individuals treated with roflumilast foam achieved Scalp-Investigator Global Assessment (S-IGA) Success compared to 28.1%
Lipocine Announces Realignment And Forward Focus On Treating CNS Disorders; Announces Planned Monetization Of Non-Core Assets Through Partnerships
Company to apply its proprietary Lip'ral oral drug delivery technology to advance a pipeline of differentiated products for Central Nervous System (CNS) disorders
Initial focus on oral delivery of neuroactive
Profound Medical Highlights Four Year Follow-Up Data From TACT Pivotal Clinical Trial
TORONTO, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets
AC Immune Partner LMI Progresses Tau PET Tracer PI-2620 Into Late-Stage Development In Alzheimer’s Disease
AC Immune’s Tau PET tracer moves closer to becoming a next generation diagnostic for Alzheimer’s Disease (AD)
AC Immune to receive a milestone payment from LMI for progress into late-stage product
Purple Innovation Announces Formation Of Special Committee To Evaluate Unsolicited Takeover Proposal From Coliseum Capital Management
LEHI, Utah, Sept. 26, 2022 /PRNewswire/ -- Purple Innovation, Inc. (NASDAQ:PRPL) ("Purple" or the "Company"), a comfort innovation company known for creating the "World's First No